Three days after optogenetics won the Nobel Prize in Physiology or Medicine, the technique got its first large test in people. The New England Journal of Medicine published on October 8 the results of a trial in which 10 legally blind patients received an optogenetic gene therapy, according to the University of Pittsburgh. The answer is more modest than the Nobel headlines, and more interesting.

From algae to the eye

The Nobel Assembly at Karolinska Institutet honored Karl Deisseroth of Stanford, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg on October 5. Hegemann and Nagel found a light-sensitive protein, channelrhodopsin, in a single-celled alga, and Deisseroth turned it into a switch for nerve cells, the committee said. The prize recognized a research tool, one that lets scientists turn individual neurons on or off with light in a living brain.

The committee's own release noted that researchers are using the method in attempts to restore sight, the Ophthalmology Times reported. That is what the NEJM paper tests, and it is a different question from what the Nobel rewarded. Using light to study a mouse brain is one thing. Using it to give a blind person something to see is another.

What the trial did

The patients had advanced retinitis pigmentosa, an inherited disease that destroys the eye's light-detecting rods and cones, and were left with little or no vision, per the Pittsburgh release. Each received one injection into the worse-seeing eye. The injection carried a gene for a light-sensitive protein into retinal ganglion cells, which normally pass signals to the brain but cannot detect light themselves.

That detail is the point. José-Alain Sahel, director of the UPMC Vision Institute and the study's first author, said many cells in the retina survive for years after photoreceptors die, and the therapy bypasses the damaged ones. Because it does not depend on which mutation caused the disease, it could in principle help patients whatever their genetics. Retinitis pigmentosa has more than 100 known causative mutations, and Sahel noted that developing a separate treatment for each is proving very difficult and costly.

Ordinary light is not enough on its own, so patients also wear a specially designed visual stimulation device, goggles that deliver tailored light to the treated cells. In the original 2021 case, a researcher noted that an injection without the goggles would have looked like a failure. The trial, named PIONEER, was funded by GenSight Biologics of Paris.

What the numbers show

Seven of the 10 participants had better light sensitivity after treatment, by factors from 2.0 to 62.3, according to Physics World's summary of the paper, and six improved by an amount considered clinically meaningful. Some patients also performed better at detecting, locating and touching objects such as a notebook and a staple box when wearing the goggles.

On safety, 34 adverse events were recorded in nine of the 10 participants, including 23 mild and 10 moderate events, which were mostly temporary inflammation and short-lived rises in eye pressure, Inside Precision Medicine reported.

Treat these results as encouraging, not as a cure. Medical Xpress's summary of the paper states that normal vision was not restored. A patient who goes from a faint awareness of light to locating a notebook on a table has gained something real, but not the ability to read or recognize faces.

What it does not tell us

This was a phase 1/2 dose-escalation study. The primary aim was safety. GenSight's own announcement described the visual outcomes as exploratory. There was no control group and no masking, which makes it harder to separate treatment effect from patients' effort, training or expectations. Ten patients is also a small number to generalize from, particularly in a disease with such varied causes.

Another limitation is built into the design. The gain depends on wearing the device. In the 2021 Nature Medicine case report that preceded this trial, a 58-year-old man with 40 years of retinitis pigmentosa could locate and touch objects only when he wore the goggles. The therapy is not a restored retina. It is a gene therapy plus a wearable prosthetic, and both have to work, be affordable and be approved.

That raises questions the paper cannot answer: how long the effect lasts, whether it can be repeated if needed, and what a regulator will accept as a meaningful endpoint when vision gains are measured in light sensitivity rather than in letters on a chart.

Why the timing matters

Prize committees reward a discovery after its value is clear, and that clarity is still arriving for optogenetics in medicine. The NEJM paper builds on a 2021 case report that Pittsburgh describes as the first clinical use of optogenetics, which means the path from the first patient to a published cohort took about five years.

Botond Roska and Sahel, the two scientists behind much of this work, also received the 2026 António Champalimaud Vision Award this year, the Ophthalmology Times noted. Vision is the first place where optogenetics can be judged by the thing patients care about. A bigger, controlled trial that shows durable gains in daily tasks would turn a Nobel-winning tool into a medicine. Until then, it remains a promising prototype.

---